Nuvalent (NUVL) EPS (Weighted Average and Diluted) (2020 - 2026)
Nuvalent (NUVL) reported EPS (Weighted Average and Diluted) of -$1.39 for Q1 2026, down 17.8% on a YoY basis from -$1.69 in Q1 2025, and up 12.03% quarter-over-quarter from -$1.58 in Q4 2025.
Nuvalent (NUVL) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Nuvalent has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$1.39 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 17.8% year-over-year to -$1.39; the trailing twelve-month figure through Mar 2026 stood at -$6.06 (down 37.73% YoY), and the FY2025 full-year result was -$5.85, down 48.85% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$1.39, up from -$1.58 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.36 in Q1 2022, with the low at -$1.7 in Q3 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.88 across 5 years, with a median of -$0.69 in 2024.
- The largest YoY upside for EPS (Weighted Average and Diluted) was 88.01% in 2022 against a maximum downside of 484.62% in 2022.
- Nuvalent's EPS (Weighted Average and Diluted) stood at -$0.5 in 2022, then declined by 24.0% to -$0.62 in 2023, then plunged by 70.97% to -$1.06 in 2024, then tumbled by 49.06% to -$1.58 in 2025, then grew by 12.03% to -$1.39 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.39 (Q1 2026), -$1.58 (Q4 2025), and -$1.7 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | -1.39 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.39 |
| Dec 31, 2025 | -1.58 |
| Sep 30, 2025 | -1.70 |
| Jun 30, 2025 | -1.39 |
| Mar 31, 2025 | -1.18 |
| Dec 31, 2024 | -1.06 |
| Sep 30, 2024 | -1.28 |
| Jun 30, 2024 | -0.88 |
| Mar 31, 2024 | -0.69 |
| Dec 31, 2023 | -0.62 |
| Sep 30, 2023 | -0.59 |
| Jun 30, 2023 | -0.51 |
| Mar 31, 2023 | -0.44 |
| Dec 31, 2022 | -0.50 |
| Sep 30, 2022 | -0.41 |
| Jun 30, 2022 | -0.38 |
| Mar 31, 2022 | -0.36 |
| Dec 31, 2021 | 0.13 |
| Sep 30, 2021 | -0.39 |
| Jun 30, 2021 | -3.17 |